Lactobacillus salivarius UCC118™ Dampens Inflammation and Promotes Microbiota Recovery to Provide Therapeutic Benefit in a DSS-Induced Colitis Model.

ABSTRACT: The use of probiotics such as Lactobacillus and Bifidobacterium spp. as a therapeutic against inflammatory bowel disease (IBD) is of significant interest. Lactobacillus salivarus strain UCC118^TM is a commensal that has been shown to possess probiotic properties in vitro and anti-infective properties in vivo. However, the usefulness of UCC118 ^TM as a therapeutic against colitis remains unclear. This study investigates the probiotic potential of Lactobacillus salivarius, UCC118™ in a mouse model of colitis. DSS-induced colitis was coupled with pre-treatment or post-treatment with UCC118^TM by daily oral gavage. In the pre-treatment model of colitis, UCC118^TM reduced the severity of the disease in the early stages. Improve

SUBMITTER: Iyer N 

PROVIDER: S-EPMC9324116 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature